Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay

Use of bacterially expressed EBNA‐1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients

“…EBNA-1 was chosen because it is the only antigen expressed in all EBV associated tumors . A similar approach was reported by Cheng et al [1993]. They chose a 20-amino acid synthetic peptide p107 (aa 269±288, which is within the Gly-Ala repeats of EBNA-1) for ELISA and demonstrated that 90% of Malaysian NPC sera were positive using that test.…”

The disease associations of the antibody response against the Epstein--Barr virus transactivator protein ZEBRA can be separated into different epitopes

“…In the case of NPC, early detection is critical for the outcome and screening for NPC using EBV serology (IgA/VCA) has been thoroughly evaluated (Zeng et al, 1983(Zeng et al, , 1985. Both IgG anti-ZEBRA (Mathew et al, 1994) and IgA anti-EBNA-1 (Cheng et al, 1993) can be used to complement the IgA/VCA test, since they both have a high predictive value for NPC and since a substantial proportion of IgA/VCA-negative NPC cases are positive for IgG/ZEBRA or IgA/EBNA-1. However, both IgA/ VCA (Marklund et al, 1986), IgG/ZEBRA (Joab et al, 1991 a) and IgA/EBNA-1 (unpublished observation) are regularly positive in IM patients.…”

Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody

“…These were based on antibodies to different antigenic components of the EBV (9,(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). Attempts to use panels of antibody-based markers have generally been useful in improving the accuracy of NPC detection (13, 15, 20, 21, 29 -32 ).…”